STOCK TITAN
  1. Home
  2. News
  3. PFE

Pfizer Inc. - PFE STOCK NEWS

Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.

Pfizer Inc. (PFE), headquartered at The Spiral in Manhattan, New York City, is a leading American multinational pharmaceutical and biotechnology corporation established in 1849 by Charles Pfizer and his cousin Charles F. Erhart. Pfizer stands as one of the world's largest pharmaceutical companies, with annual sales nearing $50 billion, excluding COVID-19 product sales.

Pfizer's core business revolves around the development, manufacturing, and global distribution of prescription drugs and vaccines. Its top-selling products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. These products contribute significantly to Pfizer's global sales, with nearly 50% of revenues coming from international markets, and emerging markets playing a crucial role.

In recent news, Pfizer continues to make strides in cancer treatment through its collaboration with Astellas and Merck. A key focus has been on the promising cancer therapeutic combinations involving PADCEV™ (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab), targeting metastatic urothelial cancer. This collaboration underscores Pfizer's commitment to advancing cancer treatments and improving patient outcomes worldwide.

Financially, Pfizer remains robust, continually investing in research and development to innovate and expand its portfolio of treatments addressing unmet medical needs. Strategic partnerships and collaborations further enhance its position in the market, ensuring a steady pipeline of new and effective therapeutic solutions.

With a rich history and a steadfast commitment to healthcare innovation, Pfizer Inc. continues to be a significant player in the pharmaceutical industry, dedicated to improving global health through advanced medical research and groundbreaking therapies.

News

European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Rhea-AI Summary
Pfizer and Astellas announced that the European Medicines Agency has validated for review a Type II variation application for PADCEV with KEYTRUDA as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer. The combination significantly extended overall and progression-free survival, potentially offering an alternative to platinum-containing chemotherapy. The application is based on results from the Phase 3 EV-302 clinical trial, demonstrating statistically significant and clinically meaningful results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation

Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) has received an unsolicited mini-tender offer from TRC Capital Investment Corporation to purchase up to 4 million shares of Pfizer common stock at a price of $27.35 per share in cash. The offer price is approximately 4.4 percent lower than the closing share price on December 27, 2023. Pfizer does not endorse the offer and recommends that stockholders do not tender their shares due to the offer being below the current market price and subject to numerous conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
-
News

TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer

Rhea-AI Summary
Genmab A/S (GMAB) and Pfizer, Inc. (PFE) announced that the FDA has accepted the sBLA for TIVDAK, with a PDUFA action date of May 9, 2024. This is based on positive results from the global phase 3 innovaTV 301 trial, demonstrating an overall survival benefit of tisotumab vedotin-tftv over chemotherapy for the treatment of patients with recurrent or metastatic cervical cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
News

TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer

Rhea-AI Summary
Pfizer Inc. (PFE) and Genmab A/S (GMAB) announced the FDA's acceptance of the supplemental Biologics License Application (sBLA) seeking to convert the accelerated approval of TIVDAK to full approval for the treatment of patients with recurrent or metastatic cervical cancer with disease progression. The Phase 3 innovaTV 301 trial demonstrated a favorable benefit/risk profile, including improvement in overall survival, progression-free survival, and confirmed objective response rate in patients with previously treated recurrent or metastatic cervical cancer compared to chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
-
News

European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer

Rhea-AI Summary
Pfizer Inc. (PFE) announced that the European Commission has approved TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in the European Union. The approval was based on data from the Phase 3 TALAPRO-2 trial, showing a 37% reduction in the risk of disease progression or death with TALZENNA plus XTANDI compared to placebo plus XTANDI, meeting the primary endpoint of improving radiographic progression-free survival. The safety profile of TALZENNA plus XTANDI was consistent with the known safety profile of each medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
-
News

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 3:00 p.m. PST. The webcast will be available on www.pfizer.com/investors, and the transcript and webcast replay will be accessible for at least 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.27%
Tags
conferences
News

Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts

Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 30, 2024. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2023 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
conferences
-
News

PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer

Rhea-AI Summary
Pfizer Inc. (PFE) and Astellas Pharma Inc. (4503) announced that the U.S. FDA has approved PADCEV plus pembrolizumab for the treatment of adult patients with locally advanced or metastatic urothelial cancer. The combination nearly doubled median overall survival and median progression-free survival compared to standard platinum-based chemotherapy, marking a paradigm shift in the treatment of advanced bladder cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
-
News

Pfizer Declares First-Quarter 2024 Dividend

Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) has announced an increase in its quarterly cash dividend to $0.42 per share for the first quarter of 2024. The dividend will be payable on March 1, 2024, to shareholders of record as of January 26, 2024. This marks the 341st consecutive quarterly dividend paid by Pfizer. Dr. Albert Bourla, Pfizer's Chairman and CEO, expressed the company's commitment to returning value to its shareholders through dividend increases for the past fifteen years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
dividends
News

Pfizer Completes Acquisition of Seagen

Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) has completed the acquisition of Seagen Inc. (NASDAQ: SGEN) for $43 billion, solidifying its position as a leading oncology company. The acquisition brings Seagen's world-leading Antibody-Drug Conjugate (ADC) technology and four in-line medicines to Pfizer's oncology portfolio. Dr. Albert Bourla, Pfizer's Chairman and CEO, emphasizes the company's commitment to delivering breakthrough treatments for cancer, with Oncology expected to be a significant growth driver for Pfizer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
acquisition

FAQ

What is the current stock price of Pfizer (PFE)?

The current stock price of Pfizer (PFE) is $26.41 as of January 14, 2025.

What is the market cap of Pfizer (PFE)?

The market cap of Pfizer (PFE) is approximately 151.1B.

What is Pfizer Inc. known for?

Pfizer Inc. is known for its development, manufacturing, and distribution of prescription drugs and vaccines, including Prevnar 13, Ibrance, and Eliquis.

Where is Pfizer's headquarters located?

Pfizer's headquarters are located at The Spiral in Manhattan, New York City.

How much does Pfizer make annually?

Pfizer's annual sales are close to $50 billion, excluding COVID-19 product sales.

What are some of Pfizer's top-selling products?

Some of Pfizer's top-selling products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis.

What is the significance of Pfizer's international sales?

Pfizer's international sales represent nearly 50% of its total sales, with emerging markets being a major contributor.

What recent collaborations has Pfizer been involved in?

Pfizer has recently been involved in collaborations with Astellas and Merck to develop and commercialize cancer treatments like PADCEV™ and KEYTRUDA®.

When was Pfizer founded?

Pfizer was founded in 1849 by Charles Pfizer and Charles F. Erhart.

What is Pfizer's approach to innovation?

Pfizer continually invests in research and development to innovate and expand its portfolio of treatments addressing unmet medical needs.

How does Pfizer contribute to cancer treatment?

Pfizer contributes to cancer treatment through its development of innovative therapies and strategic collaborations, notably involving PADCEV™ and KEYTRUDA®.

What role do strategic partnerships play for Pfizer?

Strategic partnerships enhance Pfizer's market position, ensuring a steady pipeline of new and effective therapeutic solutions.
Stock PFE logo
Pfizer Inc.

NYSE:PFE

PFE Rankings

#70 Ranked by Market Cap
#420 Ranked by Dividends

PFE Stock Data

151.15B
5.66B
0.05%
67.79%
1.51%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
NEW YORK